These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 31435998

  • 1. Defining polycystic ovary syndrome phenotype in Vietnamese women.
    Cao NT, Le MT, Nguyen VQH, Pilgrim J, Le VNS, Le DD, Pham CK, Aharon D, Hill MJ.
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2209-2219. PubMed ID: 31435998
    [Abstract] [Full Text] [Related]

  • 2. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
    Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J.
    Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
    [Abstract] [Full Text] [Related]

  • 3. Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study.
    Bhide P, Kulkarni A, Dilgil M, Dhir P, Shah A, Gudi A, Homburg R.
    Gynecol Endocrinol; 2017 Oct; 33(10):801-806. PubMed ID: 28454499
    [Abstract] [Full Text] [Related]

  • 4. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
    Lie Fong S, Laven JSE, Duhamel A, Dewailly D.
    Hum Reprod; 2017 Aug 01; 32(8):1723-1731. PubMed ID: 28854584
    [Abstract] [Full Text] [Related]

  • 5. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
    Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A.
    J Clin Endocrinol Metab; 2005 May 01; 90(5):2571-9. PubMed ID: 15713728
    [Abstract] [Full Text] [Related]

  • 6. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D.
    Hum Reprod; 2017 Aug 01; 32(8):1716-1722. PubMed ID: 28854589
    [Abstract] [Full Text] [Related]

  • 7. Elevated anti-Mullerian hormone in lean women may not indicate polycystic ovarian syndrome.
    Bradbury RA, Lee P, Smith HC.
    Aust N Z J Obstet Gynaecol; 2017 Oct 01; 57(5):552-557. PubMed ID: 28597496
    [Abstract] [Full Text] [Related]

  • 8. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H, Tanir HM, Yildiz Z.
    Arch Gynecol Obstet; 2006 Jul 01; 274(4):227-32. PubMed ID: 16691383
    [Abstract] [Full Text] [Related]

  • 9. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome.
    Le MT, Le VNS, Le DD, Nguyen VQH, Chen C, Cao NT.
    Clin Endocrinol (Oxf); 2019 Apr 01; 90(4):579-585. PubMed ID: 30636332
    [Abstract] [Full Text] [Related]

  • 10. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study.
    Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K.
    Hum Reprod; 2013 Apr 01; 28(4):1077-83. PubMed ID: 23377771
    [Abstract] [Full Text] [Related]

  • 11. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ, Stojanović N, Duhamel A, Dewailly D.
    Hum Reprod; 2015 Aug 01; 30(8):1927-33. PubMed ID: 26048913
    [Abstract] [Full Text] [Related]

  • 12. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.
    Akush Ginekol (Sofiia); 2013 Aug 01; 52 Suppl 1():16-23. PubMed ID: 24294740
    [Abstract] [Full Text] [Related]

  • 13. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
    Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T.
    Arch Gynecol Obstet; 2016 Feb 01; 293(2):447-56. PubMed ID: 26408006
    [Abstract] [Full Text] [Related]

  • 14. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
    Dewailly D, Alebić MŠ, Duhamel A, Stojanović N.
    Hum Reprod; 2014 Nov 01; 29(11):2536-43. PubMed ID: 25267785
    [Abstract] [Full Text] [Related]

  • 15. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R, Zanotti L, Fanelli F, Mezzullo M, Fazzini A, Morselli Labate AM, Repaci A, Ribichini D, Gambineri A.
    J Clin Endocrinol Metab; 2016 May 01; 101(5):2013-22. PubMed ID: 26964728
    [Abstract] [Full Text] [Related]

  • 16. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
    Parahuleva N, Pehlivanov B, Orbecova M, Uchikova E, Ivancheva H.
    Akush Ginekol (Sofiia); 2014 May 01; 53(5):22-7. PubMed ID: 25558667
    [Abstract] [Full Text] [Related]

  • 17. Revised criteria for PCOS in WHO Group II anovulatory infertility - a revival of hypothalamic amenorrhoea?
    Lauritsen MP, Pinborg A, Loft A, Petersen JH, Mikkelsen AL, Bjerge MR, Nyboe Andersen A.
    Clin Endocrinol (Oxf); 2015 Apr 01; 82(4):584-91. PubMed ID: 25262871
    [Abstract] [Full Text] [Related]

  • 18. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
    Bell RJ, Islam RM, Skiba MA, Herbert D, Martinez Garcia A, Davis SR.
    Hum Reprod; 2021 Dec 27; 37(1):109-118. PubMed ID: 34741176
    [Abstract] [Full Text] [Related]

  • 19. Effects of supervised aerobic training on the levels of anti-Mullerian hormone and adiposity measures in women with normo-ovulatory and polycystic ovary syndrome.
    Al-Eisa E, Gabr SA, Alghadir AH.
    J Pak Med Assoc; 2017 Apr 27; 67(4):499-507. PubMed ID: 28420905
    [Abstract] [Full Text] [Related]

  • 20. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
    Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H.
    Acta Obstet Gynecol Scand; 2013 Dec 27; 92(12):1369-74. PubMed ID: 23980726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.